Trishula Therapeutics, Inc.
8 employees on LinkedIn · 4 known investors
Find your way into Trishula Therapeutics, Inc.
Sign up to see every warm intro you have to Trishula Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Trishula Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers. It focuses on oncology and immunotherapy drug development.
Founders & leadership

Investors · 4
How we know: Canaan Partners's portfolio page · the company's own site · a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: MPM BioImpact's portfolio page · the company's own site · Not right? Tell us
How we know: Lightstone Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Related companies · 2
Companies working in the same space as Trishula Therapeutics, Inc..
In the news
Frequently asked questions
- What does Trishula Therapeutics, Inc. do?
- Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers. It focuses on oncology and immunotherapy drug development.
- Who are Trishula Therapeutics, Inc.'s investors?
- Trishula Therapeutics, Inc.'s investors include Canaan Partners, MPM BioImpact, Astellas Venture Management LLC, Lightstone Ventures.




